In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Miryam Paola Alvarez-FloresCentre of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0002-7986-923X Amanda Teixeira de MeloCentre of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0003-3867-8522 Renata Nascimento GomesCentre of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0003-0474-1896 Thatiana Corrêa de MeloCentre of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0001-7002-5180 Douglas Souza OliveiraCentre of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0001-8919-4996 Marcelo Medina de SouzaCentre of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo 05503-900, Brazil.
Carlos DeOcesano-PereiraCentre of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0002-8933-4474 Mauricio Barbugiani GoldfederDevelopment and Innovation Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0009-0002-3731-0849 Fernanda FariaDevelopment and Innovation Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0001-6993-6323 Ana Marisa Chudzinski-TavassiCentre of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0001-7717-7013 Funding
Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/07467-1Fundação de Amparo à Pesquisa do Estado de São Paulo 2015/50040-4Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/13139-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2022/16532-0National Council for Scientific and Technological Development 303197/2017-0
6 · The paper itselfAbstract
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive cartilage loss, extracellular matrix degradation, chondrocyte apoptosis, and elevated inflammatory mediators. Chondrocytes respond to IL-1β and other inflammatory signals by secreting cytokines and activating transcriptional pathways that perpetuate inflammation. Because current therapies do not prevent OA progression, bioactive compounds with cytoprotective and immunomodulatory activity are of considerable interest.
Indexed as
ChondrocytesCytoskeletonInflammationbeta CateninCells, CulturedCytokinesHumansInterleukin-1betaInterleukin-8rab GTP-Binding Proteinsrac1 GTP-Binding ProteinrhoA GTP-Binding Proteinbeta CateninCytokinesInterleukin-1betaInterleukin-8rab GTP-Binding Proteinsrac1 GTP-Binding ProteinrhoA GTP-Binding Proteinchondrocytescytokinescytoskeletal pathwaysIL-1βinflammatory responsesLonomiaRac-1RhoAβ-catenin
Identifiers
PMID41596581
PMCPMC12841748
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390